ins‐3001 efficiently inhibits severe vascular...

1
INS‐3001 efficiently inhibits severe vascular calcifications by direct interference with vessel wall calcification Materials and Methods Background and Aim Results 1 Laboratory of Pathophysiology, University of Antwerp, Belgium 2 Inositec AG, Zurich, Switzerland www.pathophysiology.be Poster Design: Dirk De Weerdt Poster 816 Prevention/treatment of vascular media calcification currently is based on controlling its most important risk factors. A new therapeutic approach with potential higher efficacy consists in the administration of molecules directly interfering with the calcification process in the medial layer of the vessel wall, such as INS‐3001. This poster reports about the administration of INS‐3001 in a rat model of vitamin D‐warfarin induced vascular media calcifications (pooled data of 3 independent studies). Calcification was induced in male rats (8 weeks) by warfarin (3 mg/g diet) administration during 5 days and by 4 consecutive daily administrations of vitD3 (100.000 IU/kg) starting on day 1 of the warfarin administration. Rats were randomly assigned to different groups: vehicle, and INS‐ 3001 groups of 1x12.5, 1x25, 2x25, 1x50 and 2x50 mg/kg/day. Treatment was administered sc. during 7 days. Animals were sacrificed after 7 days. Vascular calcification was evaluated on Von Kossa stained tissue sections of the thoracic/abdominal aorta and by measurement of the total Ca content of the thoracic/abdominal aorta and the carotid/femoral arteries by atomic absorption spectrometry. Calcaemic status was checked for 30 min after the first treatment administration in the vehicle and the INS‐3001 1x50 mg/kg/day group, by measuring ionized calcium (i‐STAT point of care analysis). In the figure below a schematic overview of the study set‐up is presented. INS‐3001 is a promising molecule for the treatment of vascular calcifications. The inhibitory effect is expected to be independent of the underlying cause of calcifications. Anja VERHULST 1 , Mattias E. IVARSSON 2 , Roberto MAJ 2 , Ellen NEVEN 1 , Patrick C. D’HAESE 1 Contact: [email protected] Conclusion Mortality rate was 38% (15/40) in the vehicle group, 42% (5/12) in the 1x12.5 mg/kg/day dose group, 33% (4/12) in the 1x25 mg/kg/day dose group, 21% (4/19) in the 1x50 mg/kg/day dose group, 15% (3/19) in the 2x50 mg/kg/day dose group and 0% (0/18) in the 2x25 mg/kg/day dose group. Kaplan Meier survival analysis found the mortality rate in the latter group to be significantly different from the vehicle group (p = 0.04). Figure 1: Kaplan Meier survival plot. *p<0.05 vs vehicle. Calcification in the medial layer of the thoracic aorta was significantly lower on Von Kossa stained sections (area% positivity) of INS‐3001 groups treated two times a day compared to the vehicle group (2±5%, 4±5% and 15±14% in respectively the 2x50, 2x25 mg/kg/day and the vehicle group). Total Ca content of the thoracic aorta was also significantly lower in the 2x50 mg/kg/day INS‐ 3001 dose group compared to the vehicle group (2.6±3.9 vs. 11.4±14.4 mg/g tissue. Similar results were obtained by measuring total Ca content in more peripheral arteries (a. femoralis and carotis). Figure 3: (A) Von Kossa positive area on tissue slices from the thoracic aorta. Total Ca content of the thoracic aorta (B), femoral (C) and carotid (D) artery. *p<0.05 vs CTR. Calcification in the medial layer of the abdominal aorta was significantly lower on Von Kossa stained sections (area% positivity) of the INS‐3001 treated groups compared to the vehicle group (3±5%, 8±7%, 6±4%, 15±3%, 20±3% and 28±10% in respectively the 2x50, 1x50, 2x25, 1x25, 1x12.5 mg/kg/day and the vehicle group). Total Ca content of the abdominal aorta was also significantly lower in the INS‐3001 (not the 12.5 and 25 mg/kg/day) groups compared to the vehicle group (2.8±3.7, 7.4±6.9, 6.1±5.0, 14.9±7.0, 15.6±9.4 and 14.9±7.5 mg/g tissue in respectively the 2x50, 1x50, 2x25, 1x25, 1x12.5 mg/kg/day and the vehicle group. Figure 2: (A) Von Kossa positive area on tissue slices from the abdominal aorta. (B) Total Ca content of the abdominal aorta *p<0.05 vs CTR. (C) Representative pictures of Von Kossa stained abdominal aorta sections of each treatment group. C INS‐3001 administration did not influence the calcaemic status of the animals. Serum levels of ionized calcium were similar after vehicle and INS‐3001 (50 mg/kg) administration: respectively 5.5±0.2 mg/dl and 5.4±0.2 mg/dl 30 minutes post treatment (Cmax INS‐3001).

Upload: others

Post on 12-Aug-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: INS‐3001 efficiently inhibits severe vascular ...inositec.com/wp-content/uploads/2018/10/Verhulst-et-al-ASN-2018.pdfThis poster reports about the administration of INS‐3001 in

INS‐3001 efficiently inhibits severe vascular calcifications by direct interference with vessel wall calcification

Materials and Methods

Background and Aim Results

1 Laboratory of Pathophysiology, University of Antwerp, Belgium

2 Inositec AG, Zurich, Switzerland

www.pathophysiology.be

Poster Design: Dirk De WeerdtPoster 816

Prevention/treatment of vascular media calcification currently is based on controlling its most important risk factors. A new therapeutic approach with potential higher efficacy consists in the administration of molecules directly interfering with the calcification process in the medial layer of the vessel wall, such as INS‐3001. This poster reports about the administration of INS‐3001 in a rat model of vitamin D‐warfarin induced vascular media calcifications (pooled data of 3 independent studies). 

• Calcification was induced in male rats (8 weeks) by warfarin (3 mg/g diet) administration during 5 days and by 4 consecutive daily administrations of vitD3 (100.000 IU/kg) starting on day 1 of the warfarin administration.

• Rats were randomly assigned to different groups: vehicle, and INS‐3001 groups of 1x12.5, 1x25, 2x25, 1x50 and 2x50 mg/kg/day.

• Treatment was administered sc. during 7 days. • Animals were sacrificed after 7 days.• Vascular calcification was evaluated on Von Kossa stained tissue sections of the thoracic/abdominal aorta and by measurement of the total Ca content of the thoracic/abdominal aorta and the carotid/femoral arteries by atomic absorption spectrometry.

• Calcaemic status was checked for 30 min after the first treatment administration in the vehicle and the INS‐3001 1x50 mg/kg/daygroup, by measuring ionized calcium (i‐STAT point of care analysis).

• In the figure below a schematic overview of the study set‐up is presented.

INS‐3001 is a promising molecule for the treatment of vascular calcifications. The inhibitory effect is expected to be independent of the underlying cause of calcifications.

Anja VERHULST1, Mattias E. IVARSSON2, Roberto MAJ2, Ellen NEVEN1, Patrick C. D’HAESE 1

Contact: [email protected] 

Conclusion

Mortality rate was 38% (15/40) in the vehicle group, 42% (5/12) in the 1x12.5 mg/kg/day dose group, 33% (4/12) in the 1x25 mg/kg/day dose group, 21% (4/19) in the 1x50 mg/kg/day dose group, 15% (3/19) in the 2x50 mg/kg/day dose group and0% (0/18) in the 2x25 mg/kg/day dose group.

Kaplan Meier survival analysis found the mortality rate in the latter group to be significantly different from the vehicle group (p = 0.04). 

Figure 1: Kaplan Meier survival plot. *p<0.05 vs vehicle. Calcification in the medial layer of the thoracic aortawas significantly lower on Von Kossa stained sections (area% positivity) of INS‐3001 groups treated two times a day compared to the vehicle group (2±5%, 4±5% and 15±14% in respectively the 2x50, 2x25 mg/kg/day and the vehicle group). Total Ca content of the thoracic aorta was also significantly lower in the 2x50 mg/kg/day INS‐

3001 dose group compared to the vehicle group (2.6±3.9 vs. 11.4±14.4 mg/g tissue. Similar results were obtained by measuring total Ca content in more peripheral arteries (a. femoralis and carotis).

Figure 3: (A) Von Kossa positive area on tissue slices from the thoracic aorta. Total Ca content of the thoracic aorta (B), femoral (C) and carotid (D) artery. *p<0.05 vs CTR. 

Calcification in the medial layer of the abdominal aorta was significantly lower on Von Kossa stained sections (area% positivity) of the INS‐3001 treated groups compared to the vehicle group (3±5%, 8±7%, 6±4%, 15±3%, 20±3% and 28±10% in respectively the 2x50, 1x50, 2x25, 1x25, 1x12.5 mg/kg/day and the vehicle group). Total Ca content of the abdominal aorta was also significantly lower in the INS‐3001 (not the 12.5 and 25 mg/kg/day) groups compared to the vehicle group (2.8±3.7, 7.4±6.9, 6.1±5.0, 14.9±7.0, 15.6±9.4 and 14.9±7.5 mg/g tissue in respectively the 2x50, 1x50, 2x25, 1x25, 1x12.5 mg/kg/day and the vehicle group.

Figure 2: (A) Von Kossapositive area on tissue slices from the abdominal aorta.(B) Total Ca content of the abdominal aorta *p<0.05 vs CTR.(C) Representative pictures of Von Kossa stained abdominal aorta sections of each treatment group.

C

INS‐3001 administration did not influence thecalcaemic status of the animals. Serum levels of ionized calcium were similar after vehicle andINS‐3001 (50 mg/kg) administration: respectively 5.5±0.2 mg/dl and 5.4±0.2 mg/dl 30 minutes post treatment (Cmax INS‐3001).